EUCTR2019-000991-41-GR进行中（未招募）1 期
Daratumumab combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease - The ANTARES Study
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Confirmed diagnosis of MM (IMWG consensus guidelines)
- •2. Newly diagnosed or relapsed (patients should have received a maximum of one line of prior therapy – see Appendix K) patients presenting with EMD of the skin, liver, lungs, central nervous system, lymph nodes or other tissues, but not solely paraskeletal plasmacytoma * detected by physical exam and confirmed (when required) by WBCT/MRI/PET-CT and/or biopsy**. Documentation of plasma cell infiltration is highly recommended unless it requires invasive surgical intervention such as intracerebral infiltration of plasmacytomas.
- •*Note: paraosseous plasmacytomas meet the eligibility criteria if plasma cell infiltration arising from the bone erodes bone cortex and expands into the adjacent soft tissues
- •**Note: An additional radiologic assessment at screening is not required to confirm EMD. Documentation in terms of physician’s/pathologist’s report and/or radiologic assessments performed within 42 days of C1D1 will suffice for the purposes of eligibility. All patients however will undergo a baseline radiologic assessment at C1D1 for response purposes.
- •3. Patients with one prior line of therapy must have:
- •achieved a response (PR or better based on investigator’s determination of response by the IMWG criteria) to at least one prior regimen.
- •documented evidence of PD based on Investigator’s determination of response as defined by the IMWG criteria on or after the last line of treatment.
- •4. Age = 18 years
- •5. Eastern Cooperative Oncology Group (ECOG) performance status = 2. Note: for patients with CNS involvement, an ECOG performance status >2 is also acceptable
- •6. Each patient must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study and are willing to participate in the study. Patients must be willing and able to adhere to the prohibitions and restrictions specified in this protocol, as referenced in the ICF.
- •7. Patient must have measurable disease manifested by either monoclonal protein and/or light chain in the serum or urine
- •8. Reproductive Status
- •Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test at screening. Females are not of childbearing potential if they have been in natural menopause for at least 24 consecutive months, or have had a hysterectomy and/or bilateral oophorectomy
- •Women must not be breastfeeding
- •WOCBP must agree to follow instructions for reliable methods of birth control. This includes one highly effective (< 1% failure rate per year) form of contraception (tubal ligation, intrauterine device [IUD], combined or progestogen only hormonal contraception associated with inhibition of ovulation [birth control pills, injections, hormonal patches, vaginal rings or implants] or partner’s vasectomy) and one additional effective contraceptive method (male latex or synthetic condom, diaphragm, or cervical cap). Contraception must begin 4 weeks before the start of treatment, and continue for the duration of study treatment and for 3 months after cessation of daratumumab or 12 months after cessation of cyclophosphamide, whichever is longer.
- •Males who are sexually active must always use a latex or synthetic condom during any sexual contact with females of reproductive potential, even if they have undergone a successful vasectomy. They must also agree to follow instructions for methods of contraception for 4 weeks before the start of study treatment, for the durati
排除标准
- •1. Solitary plasmacytoma
- •2. Presence of paraosseous plasmacytomas only. EXCEPTION: paraosseous plasmacytomas meet the eligibility criteria if plasma cell infiltration arising from the bone erodes bone cortex and expands into the adjacent soft tissues
- •3. Previous therapy with any anti-CD38 or anti-CS1 monoclonal antibody
- •4. Patients refractory to bortezomib based regimens (PD on or within 60 days of completion of bortezomib OR failure to achieve at least a minimal response [MR]) as the prior line of therapy
- •5. Patients who have Bortezomib or Daratumumab hypersensitivity
- •6. Patients who have active or chronic infections
- •7. Patients who have received anti-myeloma treatment within 2 weeks or 5 pharmacokinetic half-lives of the treatment, whichever is longer, before Cycle 1 Day 1 (C1D1). The only exception is emergency use of a short course of corticosteroids (equivalent of dexamethasone 40 mg/day for a maximum of 4 days) for palliative treatment before C1D1.
- •8. Previous ASCT within 12 weeks before C1D1.
- •9. Previous allogenic stem cell transplant (alloSCT) regardless of timing.
- •10. Patient has received radiotherapy within 14 days from C1D1. NOTE: Urgent localized radiotherapy for Spinal Cord Compression or Central Nervous System Involvement is allowed.
- •11. Patient has known chronic obstructive pulmonary disease (COPD) with a Forced Expiratory Volume in 1 second (FEV1) <50% of predicted normal. Note that FEV1 testing is required for patients suspected of having COPD and patients must be excluded if FEV1 <50% of predicted normal
- •12. Patient has known moderate or severe persistent asthma within the past 2 years (see) or currently has uncontrolled asthma of any classification. Note: Patients who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed in the study).
- •13. Severe cardiovascular disease (arrhythmias [CTCAE Grade 3 or higher] requiring chronic treatment, congestive heart failure [New York Heart Association (NYHA) Class III – IV] or symptomatic ischemic heart disease);
- •14. Severe pulmonary dysfunction (CTCAE grade 3-4, see appendix D);
- •15. Severe neurological or psychiatric disease;
- •16. Significant hepatic dysfunction (serum bilirubin or transaminases = 3 times the upper limit of normal [ULN]) unless related to hepatic involvement with MM.
- •Note: Patients with Gilbert Syndrome are not excluded provided that direct bilirubin is =2 x ULN.
- •17. Significant renal dysfunction (creatinine clearance <30 ml/min after rehydration) Note: refer to Appendix F for creatinine clearance calculation;
- •18. Significant bone marrow suppresion as evidenced by ANY of the below laboratory tests during screening:
- •Absolute neutrophil count =1.0 × 109/L;
- •Hemoglobin level =7.5 g/dL (=4.65 mmol/L); transfusions are NOT allowed to reach this level
- •Platelet count =75 × 109/L in patients in whom <50% of bone marrow nucleated cells are plasma cells and platelet count =50 × 109/L in patients in whom =50% of bone marrow nucleated cells are plasma cells; transfusions are NOT allowed to reach this level
- •19. Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, active systemic infection, uncontrolled hypertension, cancer, etc.) that is likely to interfere with the study procedures/results or which, in the opinion of the investigator, would constitute a hazard for participating in this study.
- •20. History of active malignancy during the past 5 years with the exception of basal carcinoma of the skin or s
研究者
相似试验
进行中（未招募）
1 期
Daratumumab combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease.Multiple Myeloma patients presenting with extramedullary diseaseMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2019-000991-41-ITSTICHTING EUROPEAN MYELOMA NETWORK40
进行中（未招募）
1 期
Daratumumab in combination with Carfilzomib, Pomalidomide and Dexamethasone (DCPD) in patients with multiple myeloma inducedacute renal failure requiring dialysis - Time Is Kidney in the Treatment of myelomA Cast nephropathy”EUCTR2020-003092-18-ATMedical University Innsbruck50
招募中
1 期
Daratumumab in combination with Carfilzomib, Pomalidomide and Dexamethasone (DCPD) in patients with multiple myeloma induced acute renal failure NOT requiring dialysisEUCTR2022-004207-32-ATMedical University Innsbruck, Internal Medicine V50
进行中（未招募）
1 期
DAratumumab iN combination with BorTEzomib and Dexamethasone in subjects with relapsed or relapsed and refractory Multiple Myeloma and severe renal impairment including subjects undergoing hemodialysis. A phase 2, open-label, multicenter trialMedDRA version: 21.1Level: PTClassification code 10035226Term: Plasma cell myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Multiple MyelomaEUCTR2016-000433-51-GRniversity Medical Center Hamburg-Eppendorf36
进行中（未招募）
1 期
DAratumumab iN combination with BorTEzomib and Dexamethasone in subjects with relapsed or relapsed and refractory Multiple Myeloma and severe renal impairment including subjects undergoing hemodialysis. A phase 2, open-label, multicenter trialMultiple MyelomaEUCTR2016-000433-51-DEniversity Medical Center Hamburg-Eppendorf36